Effects of Dexmedetomidine on Delirium Duration of Non-intubated ICU

Status Completed

Clinical Trial Summary

The primary purpose of the study is to evaluate whether dexmedetomidine is effective in treating agitated delirium of non-intubated ICI patients

Clinical Trial Description

Delirium during intensive care unit (ICU) stay is frequent and associated with significant morbidity, mortality and healthcare related costs. International guidelines suggest its prevention. However, curative treatment remains unclearly established. Despite a non-unequivocal literature, haloperidol is the first line recommended neuroleptic. Dexmedetomidine, an alpha2-adrenergic receptors agonist has shown its efficiency in the treatment of delirium in intubated patients but also in its prevention. Dexmedetomidine represents a widely used alternative to haloperidol. Only few studies have compared the efficacy of dexmedetomidine in non-intubated ICU patients as a first line curative treatment of delirium. Main objective of 4D trial is to demonstrate that dexmedetomidine decreases delirium duration compared to placebo. The 4D trial is an investigator-initiated, prospective, multicenter, randomized, double-blinded, two-arm trial, randomizing 300 non-intubated ICU patients with diagnosis of agitated delirium to receive dexmedetomidine or placebo as a cure. The primary outcome measure is a composite of duration of agitation or delirium or the use of intubation with deep sedation and mechanical ventilation. Secondary outcomes include mortalities at 7 and 28 days, ICU length of stay and occurrence of adverse effects. The sample size will allow the detection of a 50% decrease of agitation duration (120 minutes), of an absolute reduction of delirium duration (1 day) and of a 50% relative decrease of intubation and mechanical ventilation, with a type 1 error rate of 1.8 % (error risk inflation due to components of composite) and power of 90 %, assuming a 15 % incidence of intubation and mechanical ventilation requirements, an agitation duration of 240 minutes and a delirium duration of 3 days. One hundred and 10 patients by group will be needed. A intermediate analysis is scheduled and requires the inclusion of 150 patients in each group. The 4D trial may provide important data on the safety of commonly used sedative dexmedetomidine and could have a significant impact on future treatment of non-intubated ICU patients presenting with agitated delirium. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03317067
Study type	Interventional
Source	University Hospital, Clermont-Ferrand
Contact
Status	Completed
Phase	Phase 3
Start date	December 21, 2017
Completion date	February 23, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04551508` - Delirium Screening 3 Methods Study
Recruiting	`NCT05891873` - Delirium in the (Neuro)Intensive/Critical Care in the Adult and Paediatric Czech Populations
Recruiting	`NCT06027788` - CTSN Embolic Protection Trial	N/A
Recruiting	`NCT04792983` - Cognition and the Immunology of Postoperative Outcomes
Recruiting	`NCT06194474` - Study on Biomarkers of Postoperative Delirium in Elderly Cardiac Surgery Patients
Completed	`NCT03095417` - Improving the Recovery and Outcome Every Day After the ICU	N/A
Completed	`NCT05395559` - Prevalence and Recognition of Cognitive Impairment in Hospitalized Patients: a Flash Mob Study
Terminated	`NCT03337282` - Incidence and Characteristics of Postoperative Cognitive Dysfunction in Elderly Quebec Francophone Patients
Not yet recruiting	`NCT04846023` - Pediatric Delirium Screening in the PICU Via EEG	N/A
Not yet recruiting	`NCT04538469` - Absent Visitors: The Wider Implications of COVID-19 on Non-COVID Cardiothoracic ICU Patients, Relatives and Staff
Not yet recruiting	`NCT03807388` - ReMindCare App for Patients From First Episode of Psychosis Unit.	N/A
Withdrawn	`NCT02673450` - PER3 Clock Gene Polymorphism, Clock Gene Expression and Delirium in the Intensive Care Unit.
Recruiting	`NCT03256500` - Transcranial Direct Current Stimulation for the Treatment of Delirium	N/A
Not yet recruiting	`NCT02892968` - ED Ultrasonographic Regional Anesthesia to Prevent Incident Delirium in Hip Fracture Patients	N/A
Completed	`NCT02890927` - Geriatric-CO-mAnagement for Cardiology Patients in the Hospital	N/A
Recruiting	`NCT03165539` - Cerebral Oxygen Desaturation and Post-Operative Delirium in Thoracic Surgical Patients
Completed	`NCT02554253` - The Impact of Ketamine on Postoperative Cognitive Dysfunction, Delirium, and Renal Dysfunction	Phase 2
Completed	`NCT02518646` - DElirium prediCtIon in the intenSIve Care Unit: Head to Head comparisON of Two Delirium Prediction Models	N/A
Recruiting	`NCT02305589` - The Clinical Changes Before and After Sugammadex in the Patients Undergoing Hip Surgery on the Aspect of Delirium	N/A
Completed	`NCT02628925` - Nu-DESC DK: The Danish Version of the Nursing Delirium Screening Scale	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Effects of Dexmedetomidine on Delirium Duration of Non-intubated ICU Patients (4D Trial) — 4D

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms